Corcept Therapeutics INC Form 4 insider transactions

Corcept Therapeutics CEO Joseph Belanoff sold 1,974 shares of common stock at an average price of $60.8329 per share on March 24, 2025, under a pre-arranged 10b5-1 trading plan.

Sean Maduck, President of Corcept Endocrinology, reports the sale of 1,697 shares of Corcept Therapeutics stock at $60.58 per share, alongside the exercise of stock options.

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, reports the transfer of common stock to custodial accounts for a child and discloses holdings including unvested restricted stock awards.

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, reports changes in beneficial ownership of company stock due to gift transactions.

Director Daniel N. Swisher Jr. of Corcept Therapeutics exercised stock options and sold shares on March 10, 2025, according to a Form 4 filing with the SEC.

Sean Maduck, President of Corcept Endocrinology, reports stock transactions including option exercises, stock sales, and tax withholding related to restricted stock units.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, reports stock transactions including acquisitions, disposals, and option exercises.

William Guyer, Chief Development Officer of Corcept Therapeutics, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

CEO Joseph Belanoff reports selling shares and receiving stock options in Corcept Therapeutics.

Hazel Hunt, Chief Scientific Officer of Corcept Therapeutics, reports the acquisition of stock options in a recent SEC filing.

Atabak Mokari, CFO of Corcept Therapeutics, reports acquisition and disposal of company stock, including shares withheld for tax obligations and shares acquired through a purchase plan.

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, reports stock acquisitions, disposals, and option grants.

Hazel Hunt, Chief Scientific Officer of Corcept Therapeutics, exercised stock options and disposed of shares to cover the exercise price and tax obligations.

Director Daniel N. Swisher Jr. of Corcept Therapeutics exercised stock options and sold the acquired shares under a pre-arranged 10b5-1 trading plan.

Sean Maduck, President of Corcept Endocrinology, reports the acquisition and disposal of Corcept Therapeutics stock and derivative securities on February 3, 2025.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options and sold shares on February 3, 2025, according to a Form 4 filing.

Director James N. Wilson reports a gift of 7,800 common stock shares and updates beneficial ownership in Corcept Therapeutics.

Director James N. Wilson exercised stock options and transferred shares, resulting in changes to his beneficial ownership of Corcept Therapeutics stock.

Director Daniel N. Swisher Jr. exercised stock options and sold shares of Corcept Therapeutics on January 10, 2025, according to a recent SEC filing.

A Corcept Therapeutics executive, Sean Maduck, sold 20,000 shares of common stock after exercising options, according to a recent SEC filing.

Corcept Therapeutics' Chief Accounting & Technology Officer, Joseph Douglas Lyon, exercised stock options and sold shares on January 2, 2025, according to a recent SEC filing.

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, executed stock options and sold shares, according to a recent SEC filing.

Director G. Leonard Baker Jr. of Corcept Therapeutics reported a transfer of shares through a gift of limited partnership interests and holdings through a limited partnership and trust.

Director James N. Wilson reported a transfer of 7,800 common shares to a trust, maintaining indirect beneficial ownership.

Director Daniel N. Swisher Jr. exercised stock options and sold shares of Corcept Therapeutics on December 10, 2024, according to a recent SEC filing.

William Guyer, Chief Development Officer at Corcept Therapeutics, sold 309 shares of common stock to cover tax obligations related to vesting restricted stock units.

Corcept Therapeutics officer Sean Maduck reports acquiring and disposing of company stock, including shares withheld for tax obligations and new shares purchased under a company plan.

Gary Robb, Chief Business Officer at Corcept Therapeutics, reported the acquisition and disposal of company stock, including shares withheld for tax obligations and new shares purchased under a company plan.

Corcept Therapeutics' Chief Accounting & Technology Officer, Joseph Douglas Lyon, reported the acquisition and disposal of company shares on December 2, 2024.

Corcept Therapeutics' Chief Financial Officer, Atabak Mokari, reported the acquisition and disposal of company shares on December 2, 2024, including shares withheld for tax obligations and shares purchased under a company plan.